Subsequent discovery of somatic mutations in the PI3K/mTOR (PIK3CA) pathway (188), and both germline and somatic mutations in related pathways in VAs, provide further rationale for inhibiting mTOR in the treatment of isolated complex VAs not associated with overgrowth syndromes (126, 189, 190). This evidence concerns the gene MTOR and overgrowth syndrome.